Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials
Matteo Monami(Azienda Ospedaliero-Universitaria Careggi), Edoardo Mannucci(University of Florence), Alessia Scatena(Ospedale San Donato), Besmir Nreu(Azienda Ospedaliero-Universitaria Careggi), Francesco Andreozzi(The University of Texas Health Science Center at San Antonio), Barbara Cresci(Azienda Ospedaliero-Universitaria Careggi), Giorgio Sesti(Magna Graecia University)
Cited by 226
Related Papers
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study
|European Journal of Endocrinology|2011|434
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis
|European Journal of Endocrinology|2013|406
Testosterone and Metabolic Syndrome: A Meta-Analysis Study
|The Journal of Sexual Medicine|2010|395
Type 2 diabetes mellitus and testosterone: a meta-analysis study
|International Journal of Andrology|2010|369
Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials
|Diabetes Obesity and Metabolism|2010|364